金山科研平台，产品价格货期咨询微信：jinshanbio Source:Mouse myeloma cell line, NS0-derived, Glu28-Glu272 Accession #:P24593 N-terminal Sequence Analysis:Glu28 Purity:>90%, by SDS-PAGE under reducing conditions and visualized by silver stain. Predicted Molecular Mass:28 kDa SDS-PAGE:34 kDa, reducing conditions Activity:Measured by its ability to inhibit the biological activity of IGF-I or IGF-II on MCF‑7 human breast cancer cells. Karey, K.P. et al. (1988) Cancer Research 48:4083.The ED₅₀ for this effect is typically 0.5-1.5µg/mL in the presence of 14ng/mL rhIGF-II. Formulation:Lyophilized from a 0.2 µm filtered solution in Acetonitrile and TFA.See Certificate of Analysis for details. Molecule Information: IGFBP-5 Long Name: Insulin-like Growth Factor Binding Protein 5 Entrez Gene IDs: 3488 (Human); 16011 (Mouse) Background: IGFBP Family The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.